Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (836)	1/6/1999 8:40:00 AM
From: jopawa	Respond to of 2539

Monsanto Co. Reiterated 'Buy' at DLJ Princeton, New Jersey, Jan. 4 (Bloomberg Data) -- Monsanto Co. (MTC US) was reiterated ''buy'' by analyst William R. Young at Donaldson Lufkin & Jenrette Securities Corp. The 12-month target price is $58.00 per share.

To: Anthony Wong who wrote (836)	1/6/1999 8:41:00 AM
From: jopawa	Respond to of 2539

Monsanto Co. Maintained 'Outperform' at Schroder & Co. Princeton, New Jersey, Jan. 4 (Bloomberg Data) -- Monsanto Co. (MTC US) was maintained ''outperform'' by analyst Christopher H. Willis at Schroder & Co., Inc. The 12-month target price is $55.00 per share.

To: Anthony Wong who wrote (836)	1/6/1999 8:42:00 AM
From: jopawa	Respond to of 2539

Monsanto Co. Maintained 'Recommend List' at Goldman Sachs Princeton, New Jersey, Jan. 4 (Bloomberg Data) -- Monsanto Co. (MTC US) was maintained ''recommend list'' by analyst Avi Nash at Goldman, Sachs & Co.

To: Anthony Wong who wrote (836)	1/6/1999 8:46:00 AM
From: jopawa	Read Replies (1) \| Respond to of 2539

Anthony, Henry, I don't understand why companies see it necessary to selectively discuss their prospects with only their favoriate analysts. Oh well. John Monsanto Limits Conference Call Access to Selected Analysts St. Louis, Missouri, Jan. 4 (Bloomberg) -- Monsanto Co., a leading agricultural product maker focusing increasingly on pharmaceuticals, invited only selected securities analysts to a conference call in which executives discussed the future of the company's newly approved Celebrex arthritis drug. The St. Louis, Missouri-based company invited only the analysts who normally cover Monsanto and didn't notify all of its shareholders, said Lori Fisher, a spokeswoman for the company. The exclusion means smaller investors without access to Wall Street research aren't privy to the meeting's detailed discussions, which can result in significant moves in the price of a company's stock. Fisher said the company intended the conference call for analysts to follow the same format and release the same information as a call held an hour earlier for reporters. The company barred the media from the analysts' call. ''It's just always been our policy to keep that reserved for the analysts that know us,'' Fisher said. The U.S. Food and Drug Administration on Thursday approved Celebrex for treating osteoarthritis and rheumatoid arthritis. The drug, which is expected to have sales potentially topping $1 billion a year, is key to Monsanto's strategy of building up its pharmaceutical business.